Sandoz Group AG is a global leader in off-patent pharmaceuticals, operating primarily through two business segments: Generics and Biosimilars. The Generics division, which accounts for the majority of its revenue, produces active ingredients and finished dosage forms of small-molecule pharmaceuticals and anti-infectives. The fast-growing Biosimilars segment focuses on protein-based biologic therapies that offer lower-cost alternatives to branded biologics. With a geographic footprint spanning Europe, North America, and international markets, Sandoz serves wholesalers, pharmacies, and hospitals worldwide. Originally founded in 1886 and later merged into Novartis, the current legal entity was established to facilitate its 2023 spin-off as a standalone company focused purely on expanding access to affordable healthcare.
